# Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

> **NCT03739710** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 175 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Feladilimab
- **DRUG:** Ipilimumab
- **DRUG:** GSK4428859A
- **DRUG:** Dostarlimab
- **DRUG:** GSK6097608

## Key facts

- **NCT ID:** NCT03739710
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-24
- **Primary completion:** 2024-05-02
- **Final completion:** 2024-05-02
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03739710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03739710, "Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03739710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*